Drug Trial Radar · NCT07838740
A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Nov 18, 2025
Primary completion
May 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Viking Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.
Conditions
- Obese Adults
Interventions
VK2735 DrugDrug
SC or oral once daily, once weekly, every other week, or monthly
PlaceboDrug
SC or oral once daily or once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the Safety and Tolerability VK2735Time frame: 33 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Viking Clinical Site #001
Lake Forest, California · Recruiting
Viking Clinical Site #002
Miami, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.